Addition of Rezvilutamide to ADT Improves OS and rPFS Vs Bicalutamide/ADT in Hormone-Sensitive Prostate Cancer
November 30, 2022

Rezvilutamide with androgen-deprivation therapy yielded improved overall survival and radiographic progression-free survival compared with bicalutamide and androgen-deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer.

FDA Grants Investigational CAR-T Cell Therapy CB-010 2 Designations for B-Cell Non-Hodgkin Lymphoma
November 29, 2022

The allogeneic anti-CD19 CAR-T cell therapy CB-010 has received 2 designations from the FDA, including a fast-track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

Atezolizumab No Longer Available in US for a Certain Type of Bladder Cancer
November 29, 2022

Atezolizumab is no longer available to treat patients with advanced or metastatic bladder cancer following the manufacturer’s decision to withdraw its U.S. indication after consulting with the FDA.

Real-World Findings Suggest mFOLFOX6 Treatment Resulted in Less Oxaliplatin Vs Historic Control in Colon Cancer
November 29, 2022

Real-world patients with stage III colon cancer who were treated in the community practice setting with modified FOLFOX6 received less oxaliplatin vs historic controls from the phase 3 MOSAIC trial.

Race, Ethnicity ‘Notably Underreported’ in Publicly Accessible Databases of Gynecologic Cancer Trials
November 29, 2022

Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.

Jyoti S. Mayadev, MD, Discusses Multidisciplinary Focuses for Locally Advanced Cervical Cancer Following the CALLA Trial
November 29, 2022

Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.

Data Support Whole Brain Irradiation Reduction in Pediatric Cancer Survivors
November 28, 2022

Results from a pooled case control study indicate that meninges are very radiosensitive in pediatric patients who were treated at prior to age 10 years, supporting reduced dose whole brain irradiation in this population.

Treatment With Bevacizumab for 30 Months Provides No Benefit Over 15 Months in Ovarian Cancer
November 28, 2022

A longer, 30-month treatment duration with bevacizumab did not improve outcomes over the standard 15-month treatment duration in patients with newly diagnosed ovarian cancer.

FDA Issues Complete Response Letter to NDA for Poziotinib in HER2 Exon 20+ NSCLC
November 28, 2022

A complete response letter from the FDA indicated that poziotinib as a treatment for non-small cell lung cancer harboring HER2 exon 20 insertion mutations cannot be approved in its current form.

Cilta-cel Produces Early Long-Lasting Responses in Pretreated Relapsed/Refractory Multiple Myeloma
November 28, 2022

Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.